Literature DB >> 22162188

Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance.

Lin Xie1, Naotsugu Ichimaru, Miwa Morita, Jiajie Chen, Ping Zhu, Jihong Wang, Peter Urbanellis, Itay Shalev, Shizuko Nagao, Atsushi Sugioka, Liang Zhong, Norio Nonomura, Shiro Takahara, Gary A Levy, Xiao-Kang Li.   

Abstract

Here we examined whether the expression of a novel immunoregulatory gene set could be used to predict outcomes in murine models of rapamycin-induced cardiac tolerance, spontaneous hepatic tolerance, and cardiac rejection. The expression of the immunoregulatory gene set was assessed with the GeXP multiplex reverse-transcription polymerase chain reaction (RT-PCR) analysis system, and it was correlated to the pathological and biochemical parameters of the allografts. In rejecting cardiac grafts, the increased expression of an inflammatory set of genes, which included CD45, CD4, CD25, suppressor of cytokine signaling 2, cytotoxic T lymphocyte-associated protein 4 (CTLA4), selectin lymphocyte, interferon-γ (IFN-γ), programmed cell death 1 (Pdcd1), and granzyme B (Gzmb), was seen 8 days after transplantation along with histological evidence of severe allograft rejection. In tolerant cardiac allografts, the expression of fibrinogen-like protein 2 (Fgl2), Pdcd1, killer cell lectin-like receptor G1 (Klrg1), CTLA4, and lymphocyte-activation gene 3 was associated with tolerance. In a model of liver allograft tolerance, the increased expression of lectin galactose-binding soluble 1, Fgl2, CD39, phosphodiesterase 3B, Klrg1, forkhead box P3 (Foxp3), and transforming growth factor β as well as the inflammatory set of genes was observed 8 to 14 days after transplantation (ie, when there was severe inflammatory injury). At a later time when the liver allografts had been fully accepted and were histologically normal, the expression of the inflammatory set of genes returned to the baseline, but the expression of the tolerogenic set of genes was still increased. Genes that were expressed in tolerant cardiac and liver allografts included Fgl2, Klrg1, and Foxp3, whereas genes associated with rejection included CD25, Gzmb, and IFN-γ. Our data indicate that monitoring the graft expression of a novel biomarker gene set with the GeXP multiplex RT-PCR analysis system may allow differentiation between rejection and tolerance.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22162188     DOI: 10.1002/lt.22480

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

Review 1.  The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Authors:  Jiemiao Hu; Jun Yan; Ganesh Rao; Khatri Latha; Willem W Overwijk; Amy B Heimberger; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-09-26       Impact factor: 5.311

2.  The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts.

Authors:  Peter Urbanellis; Wendy Shyu; Ramzi Khattar; Jihong Wang; Anna Zakharova; Wei He; Hassan Sadozai; Achiya Z Amir; Itay Shalev; M James Phillips; Oyedele Adeyi; Heather Ross; David Grant; Gary A Levy; Andrzej Chruscinski
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

3.  Dynamic changes in gene expression and signalling during trophoblast development in the horse

Authors:  Jordan E Read; Victoria Cabrera-Sharp; Victoria Offord; Samantha M Mirczuk; Steve P Allen; Robert C Fowkes; Amanda M de Mestre
Journal:  Reproduction       Date:  2018-10-01       Impact factor: 3.906

4.  Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice.

Authors:  Junhua Wang; Dominique A Vuitton; Norbert Müller; Andrew Hemphill; Markus Spiliotis; Oleg Blagosklonov; Denis Grandgirard; Stephen L Leib; Itay Shalev; Gary Levy; Xiaomei Lu; Renyong Lin; Hao Wen; Bruno Gottstein
Journal:  PLoS Negl Trop Dis       Date:  2015-05-08

5.  Identification of microRNAs involved in acute rejection and spontaneous tolerance in murine hepatic allografts.

Authors:  Miwa Morita; Jiajie Chen; Masayuki Fujino; Yusuke Kitazawa; Atsushi Sugioka; Liang Zhong; Xiao-Kang Li
Journal:  Sci Rep       Date:  2014-10-17       Impact factor: 4.379

Review 6.  Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation.

Authors:  Xin-Guang Liu; Yu Liu; Feng Chen
Journal:  Oncotarget       Date:  2017-01-10

7.  Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells.

Authors:  Séverine Bézie; Elodie Picarda; Laurent Tesson; Karine Renaudin; Justine Durand; Séverine Ménoret; Emmanuel Mérieau; Elise Chiffoleau; Carole Guillonneau; Lise Caron; Ignacio Anegon
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

8.  Role of Regulatory T Cells (Treg) and the Treg Effector Molecule Fibrinogen-like Protein 2 in Alloimmunity and Autoimmunity.

Authors:  Andrzej Chruscinski; Hassan Sadozai; Vanessa Rojas-Luengas; Agata Bartczak; Ramzi Khattar; Nazia Selzner; Gary A Levy
Journal:  Rambam Maimonides Med J       Date:  2015-07-30

9.  A shift towards pro-inflammatory CD16+ monocyte subsets with preserved cytokine production potential after kidney transplantation.

Authors:  Elly J F Vereyken; Marina D Kraaij; Carla C Baan; Farhad Rezaee; Willem Weimar; Kathryn J Wood; Pieter J M Leenen; Ajda T Rowshani
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Endochondral Growth Defect and Deployment of Transient Chondrocyte Behaviors Underlie Osteoarthritis Onset in a Natural Murine Model.

Authors:  K A Staines; K Madi; S M Mirczuk; S Parker; A Burleigh; B Poulet; M Hopkinson; A J Bodey; R C Fowkes; C Farquharson; P D Lee; A A Pitsillides
Journal:  Arthritis Rheumatol       Date:  2016-04       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.